Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation

Osteoporosis International

Volumn 17, Issue 6, 2006, Pages 942-949

  Atamaz, F ^a   Hepguler, S ^a   Akyildiz, M ^a   Karasu, Z ^a   Kilic, M ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Alendronate; Bone fractures; Bone turnover; Liver transplantation; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCINEURIN INHIBITOR; CALCITRIOL; CALCIUM; CALCIUM GLUBIONATE; CYCLOSPORIN A; DEOXYPYRIDINOLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HIP; HUMAN; LIVER TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; PARAMETER; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; ADULT; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; FEMUR; HUMANS; LIVER TRANSPLANTATION; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PROSPECTIVE STUDIES;

EID: 33646860553     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0082-5     Document Type: Article

References (32)

1. Cheung AM (2001) Post-liver transplantation osteoporosis. J Hepatology 34:337-338
2. Delmas PD (2001) Osteoporosis in patients with organ transplants: a neglect problem. Lancet 357:325
3. Rodino MA, Shane E (1998) Osteoporosis after organ transplantation. Am J Med 104:459-469
4. Ramsey- Goldman R, Dunn JE, Dunlop DD, et al (1999) Increased risk of fracture in patients receiving solid organ transplant. J Bone Miner Res 14:456-461
5. Crippin JS (2001) Bone disease after liver transplantation. Liver Transpl 7:27
6. Epstein S (1996) Post-transplantation bone disease. The role of immunsuppressive agents on the skeleton. J Bone Miner Res 11:1-7
7. Smallwood GA, Wickman JM, Martinez E, et al (2002) Osteoporosis screening in an outpatient liver transplant clinic: Impact of primary immunsuppression. Transplant Proc 34:1569-1570
8. McDonald JA, Dunstan CR, Dilworth P, et al (1991) Bone loss after liver transplantation. Hepatology 14:613-619
9. Porayko MK, Wiesner RH, Hay JE, et al (1991) Bone disease in liver transplant recipients: Incidence, timing, and risk factors. Transplant Proc 23:1462-1465
10. Riemens SC, Oostdijk A, van Doormaal JJ, et al (1996) Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidiol. Osteoporos Int 6:213-218
11. Eastell R, Dickson ER, Hodgson SF, et al (1991) Rates of vertebral bone loss before and after liver transplanttaion in women with primary biliary cirrhosis. Hepatology 14:296-300
12. Hochberg MC, Ross PD, Black D, et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254
13. Shiraki M, Kushida K, Fukunaga M, et al (1998) A placebo-controlled, single blind study to determine to appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191-210
14. Millonig G, Graziadei IW, Eichler D, et al (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 11(8):960-966
15. Genant HK, Wu CY, van Kuijk C, et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137-1148
16. Wu CY, Li J, Jergas M, et al (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5(5):354-370
17. Genant HK, Jergas M, Palermo L, et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11(7):984-996
18. Sambrook P, Birmingham J, Kelly P, et al (1993) Prevention of corticosteroid osteoporosis-a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747-1752
19. Cohen S, Levy RM, Keller M, et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42 (11):2309-2318
20. Adachi JD, Bensen WG, Brown J, et al (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
21. Adachi JD, Bensen WG, Bianchi F, et al (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23:995-1000
22. van den Ham EC, Kooman JP, Christiaans ML (2003) The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients. Transp Int 16(2):82-87
23. Ninkovic M, Love S, Tom BD, et al (2002) Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37(1):93-100
24. Shane E, Thys- Jacobs S, Papadopoulos A, et al (1996) Antiresoptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res 11:635
25. Fan S, Almond MK, Ball E, et al (1996) Randomised prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation. J Am Soc Nephrol 7:A2714
26. Reeves HL, Francis RM, Manas DM, et al (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404-409
27. Dodidon P, Bruckner T, Hosch S, et al (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82-89
28. Monegal A, Navasa M, Guanabens N, et al (2001) Bone Disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12:484-497
29. Vedi S, Greer S, Skingle SJ, et al (1999) Mechanism of bone loss after liver transplantation: A histomorphometric analysis. J Bone Miner Res 1999 14(2):281-287
30. Feller RB, McDonald JA, Sherbon KJ, et al (1999) Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5:407
31. Crosbie OM, Freaney R, McKenna MJ, et al (1999) Predicting bone loss following orthotopic liver transplantation. Gut 44:430-434
32. Monegal A, Navasa M, Guanabens N, et al (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148-154